Pharmacokinetics of 1 -(2-Deoxy-2-fluoro-β-L-arabino-furanosyl)-5-methyluracil (L-FMAU) in Rats

Purpose. The objective of this study was to characterize the pharmacokinetics of 1 -(2-deoxy-2-fluoro--L-arabinofuranosyl)-5-methyluracil (L-FMAU), a nucleoside analogue with potent activity against the hepatitis B virus and the Epstein-Barr virus, in rats. Methods. Three doses of L-FMAU were administered intravenously (10, 25, and 50 mg/kg) to rats, and L-FMAU concentrations in plasma and urine were measured by HPLC. Pharmacokinetic parameters were generated by using area-moment analysis. Results. There were no significant differences in the pharmacokinetic parameters between the three doses ( < 0.05). Thus, the disposition of L-FMAU was linear over the dosage of 10 to 50 mg/kg. Plasma concentrations of L-FMAU declined rapidly with a terminal phase half-life of 1.33 ± 0.45 h (mean ± SD). Total clearance of L-FMAU was moderate, averaging 1.15 ± 0.28 L/h/kg. The fraction of compound excreted unchanged in urine was 0.59 ± 0.13. No glucuronide metabolite was found in the urine. The steady-state volume of distribution was 1.12 ± 0.26 L/kg indicating intracellular distribution of the compound. The fraction of L-FMAU bound to plasma proteins was approximately 15% and was independent of nucleoside concentration. Conclusions. The pharmacokinetics of L-FMAU in rats were independent of dose over the dosage range of 10 to 50 mg/kg.     

Recombinant {alpha}-interferon in renal allograft recipients with chronic hepatitis C

BACKGROUND.: Although chronic hepatitis C infection is one of the factorsthat can lead to morbidity and mortality in renal allograftrecipients, treatment procedures have not been well documented.Interferon treatment has been shown to be effective in the normalizationof biochemical hepatitis C and in the clearing of hepatitisC virus RNA. However, little is known concerning the efficacyand safety of interferon treatment in renal allograft recipientswith chronic hepatitis C. Interferon has also been accused ofincreasing renal allograft rejection. METHODS.: Recombinant -interferon in a dose of 4.5 million units threetimes per week was given to five renal-allograft recipientswith chronic hepatitis C for 6 months. Besides biochemical investigations,liver histopathologies before and after the treatment coursewere also studied. RESULTS.: Interferon treatment was effective in two of the patients, inanother two cases renal function deteriorated during the treatment.In the last case ALT increased again after cessation of interferontherapy. CONCLUSION.: We conclude that interferon seems to be moderately effectivein treating chronic hepatitis C in renal allograft recipients,but a risk of renal functional deterioration and rejection remains.     

Treatment of Vitamin B12 Deficiency after Gastric Surgery for Severe Obesity

Background: Vitamin B₁₂ deficiency after gastric surgery for obesity is due to a failure of separation of vitamin B₁₂ from protein foodstuffs and to a failure of absorption of crystalline vitamin B₁₂ in the presence of intrinsic factor. The purpose of this study was to determine which of four oral doses of crystalline vitamin B₁₂ was most effective in treating vitamin B₁₂ deficiency in 102 patients. Methods and Results: At time of entry into the study, the patients had a serum vitamin B₁₂ < 100 pmol L ⁻¹, were 29.9 ± 21.7 months post-op, were 37 ± 8 years old and had a body mass index of 30 ± 6 kg m⁻². Eight (8%) had had a vertical banded gastroplasty and 94 (92%) a gastric bypass. For the first 3 months all patients received 350 μg per day of crystalline vitamin B₁₂ and all increased their serum vitamin B₁₂ levels to over 100 pmol L⁻¹. The patients were then assigned to receive for a further 3 month period one of four oral doses of crystalline vitamin B₁₂-100 μg, 250 μg, 350 μg and 600 μg. Serum vitamin B₁₂ levels were greater than 150 pmol L⁻¹ after 6 months in 83.3% of patients who received 100 μg; 92.3% of patients who received 250 μg; 94.7% after 350 μg and 95.2% after 600 μg (p%0.525). Conclusion: At least 350 μg per day is the appropriate oral dose of crystalline vitamin B₁₂ after gastric surgery for obesity to correct low serum vitamin B₁₂ levels in 95% of patients.     

几种改进的漂浮颗粒剂灭中华按蚊和致倦库蚊的效果

目的：比较几种改进的漂浮颗粒剂灭中华按蚊和致倦库蚊幼虫的效果。方法：现场试验。结果：室内生物测定,Ｂ．ｔ．ｓ－１８７漂浮颗粒剂（荷叶型）ＬＤ５０为０．４０８７μｇ／ｍｌ,Ｂａｃｔｉｍｏｓ颗粒剂（荷叶型）ＬＤ５０为０．９３４４μｇ／ｍｌ,Ｂ．ｓ－Ｃ３－４１漂浮颗粒剂（荷叶型）ＬＤ５０为０．０５９９μｇ／ｍｌ。稻田灭中华按蚊幼虫的效果显示：两种Ｂ．ｔ．ｓ漂浮颗粒剂（荷叶型）０．８１ｇ／ｍ２剂量时,２４ｈ灭蚊效果均可达１００％。１８７漂浮颗粒剂持效可达１１ｄ,Ｂａｃｔｉｍｏｓ漂浮颗粒剂持效为８ｄ。１８７颗粒剂和Ｂ．ｓ－Ｃ３－４１颗粒剂现场灭致倦库蚊的效果显示：在０．６８ｇ／ｍ２剂量时,２４ｈ蚊幼密度下降率分别为１００％和９９．１％,持效分别为９ｄ和８ｄ。结论：采用荷叶粉为主要载体,在自然界中易于分解,不造成污染,而且灭蚊即效和持效均较好。     

早孕妇女中沙眼衣原体感染及产前诊断的研究

用PCR法对100例早孕妇女的子宫颈标本和绒毛组织进行沙眼衣原体(CT)检测,结果发现:孕妇宫颈感染率为11％(11/100),绒毛感染率为7％(7/100),在11例宫颈CT阳性的孕妇中,发现有5例绒毛CT为阳性(45.5％)。同时显示无业、个体经商者、多次妊娠(>3次)、宫颈糜烂分别是孕期感染CT的高危人群和重要因素。结论:在孕期保健中,应开展CT筛查,尤其对具有高危因素的孕妇进行检查,以利于早期发现衣原体感染,及时治疗,从而提高人口素质。     

假单胞菌医院感染的回顾性调查

目的研究影响假单胞菌医院感染发生的危险因素及防治对策,降低医院感染率。方法分析１９９５～１９９６年发生假单胞菌感染５１例,对照组１０７例在住院期间接受检查治疗的各项资料进行监测研究,通过单因素分析和Ｌｏｇｉｓｔｉｃ回归分析筛选。结果使用广谱抗生素时间,住院天数、性别、引流管的应用是有显著联系的因素。５１例假单胞菌、铜绿假单胞菌占８０．４％,并对第一代和第三代头孢菌素耐药率明显增高,对氧哌嗪青霉素和氟哌酸敏感。从医院环境微生物学监测发现墙式氧气吸入器连接口污染严重也是危险因素之一。结论严格遵守抗生素使用原则,坚持环境微生物学监测,缩短住院天数,假单胞菌所引起的医院感染是可以预防。     

抗生素在预防胸外科择期手术切口感染中的应用

目的　探讨抗生素在预防胸外科择期手术切口感染中的合理应用。方法　按Ⅰ、Ⅱ、Ⅲ类切口对635 例胸外科择期手术分组进行抗生素的种类、应用时机、术后疗程等方面切口感染率的统计比较。结果　Ⅰ、Ⅱ、Ⅲ类切口感染率分别为2.56% 、4.39% 、7.54% ;青霉素类、喹诺酮类和头孢菌素类抗生素应用,切口感染率分别为10.05% 、3.23% 、2.83% 。术后抗生素应用疗程,Ⅰ、Ⅱ类切口感染率3 天以上无差异性,Ⅲ类切口感染率5 天以上无差异性。结论　预防性抗生素应用在胸外科择期手术中有确实的临床意义;Ⅱ、Ⅲ类切口的预防性抗生素以二、三代头孢菌素类或三代喹诺酮类为好,Ⅰ类切口的预防性抗生素应用仍应首选青霉素类为宜     

干扰素防治狂犬病毒感染的小鼠实验

用小鼠试验干扰素防治狂犬病毒 (CVS)感染的作用 ,结果表明 ,小鼠在感染CVS前 2周开始使用干扰素 ,可获得 5 0 %左右的保护率 ,而在感染CVS后使用干扰素却无保护作用。干扰素与狂犬病疫苗联合使用可获得比两者单独使用更佳的保护效果 ,疫苗效力可提高 5倍以上。 5× 10 3IU剂量组与 5× 10 2 IU剂量组干扰素作用无显著差异。     

劳教吸毒人员HIV感染状况调查及有关行为因素研究

1997年 3～ 4月 ,对四川省 6所劳教所中劳教吸毒人员 164 9名调查结果表明 ,HIV抗体阳性率为 1 9%。HIV感染主要分布于 <2 0岁年龄组、文盲和农民。吸毒者中注射吸毒率为 4 8 8% ,仅使用静脉注射吸毒者HIV检出率最高 ( 5 3 % ) ,其次为既口吸又注射者 (阳性率 3 15 % )。使用毒品的原因依次为好奇占 86 4 %、引诱占8 1%、误吸 5 1%和强迫 0 5 %。使用毒品的方式与年龄、职业和收入水平有关 (P <0 0 5 ) ,而与文化程度无关。本研究首次在四川省劳教吸毒人员这一特殊人群中开展大规模HIV感染和吸毒行为调查 ,其结果对制定对该类人群的健康教育、医疗服务和管理策略将提供依据。     

血源乙型肝炎疫苗免疫持久性观察

为了解血源乙型肝炎（乙肝）疫苗的免疫持久性,对澄江县1991～1995年按照0、1、6个月免疫程序完成血源乙肝疫苗接种的人群,按接种后间隔1～5年分组,每组随机抽取100名儿童,采末梢血,共得517份免疫者的血清样品．用酶联免疫吸附试验（ELISA）检测抗-HBs、HBsAg。结果表明,接种乙肝疫苗2年内抗-HBs阳性率在90％以上,以后随间隔年眼的延长而明显下降,间隔5年降至60％,人群平均保护率达78.57％．